- Home
- AGCC vs KPTI Comparison
AGCC vs KPTI Comparison
Compare AGCC & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGCC | KPTI |
|---|---|---|
| Founded | 2020 | 2008 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 209.9M | 172.6M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | AGCC | KPTI |
|---|---|---|
| Price | $15.34 | $5.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $15.33 |
| AVG Volume (30 Days) | 189.8K | ★ 1.2M |
| Earning Date | 04-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $146,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $46.62 |
| P/E Ratio | $168.97 | ★ N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $4.23 | $3.51 |
| 52 Week High | $24.98 | $10.99 |
Technical Indicators
Market Signals| Indicator | AGCC | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 54.48 | 30.03 |
| Support Level | $13.47 | $3.93 |
| Resistance Level | $24.98 | $6.96 |
| Average True Range (ATR) | 2.83 | 0.88 |
| MACD | -0.26 | -0.39 |
| Stochastic Oscillator | 20.60 | 11.14 |
Price Performance
Historical ComparisonAbout AGCC Agencia Comercial Spirits Ltd Class A Ordinary Shares
Agencia Comercial Spirits Ltd specializes in the procurement, distribution, and sale of high-quality whiskies, including both bottled and cask whisky in both Taiwan and international markets. The company's product portfolio includes the distribution of bottled whisky, raw cask whisky, and proprietary brand whisky.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).